KLTO - Klotho Neurosciences Year-over-year earnings per share growth for the last twelve months
Klotho Neurosciences Inc (KLTO) is currently burning through its seed capital to develop anti-brain-aging platforms without generating current sales. High risks stem from the experimental nature of the proteins and the absence of revenue. Longevity patents create barriers to entry, as confirmed by the recorded quarterly EPS dynamics. Meanwhile, the 73.10 value reflects the metric's balance, demonstrating the company's fundamental momentum.
Analytical breakdowns for Klotho Neurosciences Inc
- share price and expert price forecast:
- market capitalization statistics:
- book capitalization data:
- company liabilities and liquidity data:
Total Debt to Capital Klotho Neurosciences Inc|KLTO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio anewmeds.com|KLTO - Company Aggregate Debts|Debt to Book Capitalization Ratio ANEW Medical, Inc.|KLTO - Company Long-Term Loans and Borrowings|Company Short-Term Debt Klotho Neurosciences|Quick Liquidity anewmeds.com
- earnings and valuation multiples information:
KLTO - Net Financial Result|Projected Future Earnings Klotho Neurosciences Inc|KLTO - Price to Earnings Ratio|Forward P/E Multiple anewmeds.com|KLTO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple ANEW Medical, Inc.|KLTO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Klotho Neurosciences|KLTO - Earnings per share for the last 12 months|Quarterly EPS earnings growth anewmeds.com|KLTO - Net earnings per share growth this year|Earnings growth forecast for next year Klotho Neurosciences Inc
- sales revenue and business income indicators:
Initial company analysis:Klotho Neurosciences Inc
Monitoring earnings per share (EPS) dynamics is critical for protecting capital from biotech sector volatility. The high scientific expertise of Klotho Neurosciences Inc (KLTO) management in combating neurodegeneration is validated through the percentage change in quarterly EPS, which measures net income growth rates, allowing investors to promptly identify overpayment risks or liquidity stagnation within a portfolio.
Who Klotho Neurosciences Inc competes with
BIIB: Quarterly EPS earnings growth|Neurocrine - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Regencell|Earnings per share growth in annualized terms for the last twelve months Axsome Corp AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals)|XENE (xenon-pharma.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Viking Therapeutics, Inc. VKTX|SUPN: Year-over-year earnings per share growth for the last 12 months|Catalyst Pharmaceuticals Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Denali Corp|HRMY (Harmony Biosciences) - Year-over-year net earnings per share growth for the last 12 months|biohavenpharma.com (BHVN) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Amylyx Pharmaceuticals, Inc.|TRVI: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Praxis Medicines (PRAX)|AVXL - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months CeriBell, Inc. CBLL|Year-over-year net earnings per share change for the last twelve months prothena.com (PRTA)|Alector Therapeutics - Quarterly EPS earnings growth|Annexon Biosciences (ANNX) - Year-over-year net earnings per share growth for the last 12 months|OMER: Quarterly EPS earnings growth|NGNE - Year-over-year net earnings per share change for the last twelve months|ACIU (AC Immune) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months voyagertherapeutics.com VYGR|Year-over-year earnings per share growth for the last twelve months Neumora Therapeutics, Inc. (NMRA)|Scilex Holding - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth TVGN (Tevogen Bio Holdings, Inc.)|ACOG - Year-over-year net earnings per share growth for the last 12 months|Cognition Therapeutics, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months inhibikase.com|Cassava Sciences (SAVA) - Year-over-year earnings per share growth for the last twelve months|ASRT - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months COYA|VTGN: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OVID|Year-over-year net earnings per share change for the last twelve months acumenpharm.com|Year-over-year earnings per share growth for the last twelve months CervoMed CRVO|ATHE: Year-over-year earnings per share growth for the last 12 months|Clene Nanomedicine - Quarterly EPS earnings growth|PepGen Inc. (PEPG) - Year-over-year net earnings per share growth for the last 12 months|Jupiter Neurosciences (JUNS) - Year-over-year earnings per share growth for the last twelve months|relmada.com (RLMD) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Annovis Bio|Year-over-year earnings per share growth for the last twelve months GRCE|Year-over-year net earnings per share growth for the last 12 months AIFF (Firefly Neuroscience Inc)|Year-over-year earnings per share growth rate for the last twelve months NRSN|Year-over-year earnings per share growth for the last twelve months Reviva Pharmaceuticals RVPH|MetaVia Inc. (MTVA) - Earnings per share growth in annualized terms for the last twelve months|NRXS - Year-over-year earnings per share growth for the last twelve months|HSDT (Helius Medical) - Year-over-year earnings per share growth for the last 12 months|PASG: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neuphoria Therapeutics (NEUP)|Year-over-year net earnings per share growth for the last 12 months NERV|Quarterly EPS earnings growth athira.com|Year-over-year earnings per share growth for the last twelve months Addex Therapeutics Ltd (ADXN)|ALZN (alzamend.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cyclerion Therapeutics, Inc. CYCN|Protagenic Therapeutics Inc. (PTIX) - Earnings per share growth in annualized terms for the last twelve months|KTTA - Year-over-year earnings per share growth for the last twelve months|CRGT - Quarterly EPS earnings growth|Avenue Therapeutics, Inc. (ATXI) - Year-over-year earnings per share growth for the last twelve months|BCLI (Brainstorm Cell Therapeutics Inc.) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Cara Therapeutics, Inc|Earnings per share growth in annualized terms for the last twelve months Chromocell CHRO|Year-over-year net earnings per share growth for the last 12 months ELYM (Eliem Therapeutics)|Year-over-year earnings per share growth rate for the last twelve months ITCI|Quarterly EPS earnings growth LBPH (Longboard Pharmaceuticals, Inc.)|Year-over-year earnings per one share growth for the last 12 months MRNS|NKGN - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharma|SAGE (Sage Therapeutics, Inc.) - Year-over-year net earnings per share growth for the last 12 months|synaptogen.com - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Trevena|Year-over-year earnings per share growth for the last 12 months VIGL (Vigil Neuro)|Quarterly EPS earnings growth WENA|CERE - Earnings per share growth in annualized terms for the last twelve months
